drugset / Trial / NCT04253236
To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 2 non-randomized, open-label study to investigate the efficacy, safety and tolerability of RVT-1401 in patients with Warm Autoimmune Hemolytic Anemia.
Timeline
- Start
- 2020-08-11
- Primary completion
- 2021-04-01
- Completion
- 2021-04-01
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Batoclimab | Monoclonal antibody | 340 mg | Subcutaneous |
| Subject | Batoclimab | Monoclonal antibody | 680 mg | Subcutaneous |